Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
AML
•
Hematology
•
Benign Hematology
•
Eosinophilia
What etiologies would you consider for recurrent eosinophilia and thrombocytosis in an AML patient on Aza-Ven and in remission?
https://imgur.com/paTPuCE
AML did not have eosinophilia on presentation.
Related Questions
What are your top takeaways in Hematologic Malignancies from ASH 2024?
Is there a role for CRS prophylaxis with tocilizumab during bispecific T cell engager initiation for myeloma?
Would you hold off iron chelation in a transfusion dependent MDS patient with elevated ferritin but with negative iron stain on the bone marrow?
How do you approach management for CCUS with severe cytopenias?
How would you approach fertility preservation in a young patient with DLBCL requiring R-CHOP?
How would you treat suspected secondary HLH in patients whom etoposide is contraindicated?
Should you consider thromboprophylaxis, even for low-dose lenalidomide maintenance, post-autologous transplantation?
Does tolerance of prior BTKi therapy or specific agent used (e.g., ibrutinib, acalabrutinib) influence your starting dose of pirtobrutinib?
How do you manage patients desiring home hospice but with severe thrombocytopenia and/or anemia due to advanced malignancy?
What would be an appropriate frontline AML regimen for transplant ineligible patients with chronic kidney disease (creatinine 2.5 or higher)?